CM
CMP.AU Compumedics Ltd
- Market cap
- AUD 47.9M
- P/E
- -
- P/B
- 2.11x
- ROE
- 0.9%
- Dividend yield
- -
- Fundamental score
- 1.8/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is CMP.AU undervalued?
Graham numberThe Graham number of Compumedics Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Compumedics Ltd fundamental analysis
9 of 22 checks passedROE 0/2
Low return on equity (0.9%), below 10%.
ROA 1/1
Return on assets (0.4%) is above the industry median (-35.3%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 1/1
Last year's EPS growth (114.3%) is above the 5-year average (-29.2% a year).
Earnings Growth vs Industry 1/1
Last year's EPS growth (114.3%) is above the industry median (24.9%).
Revenue Growth 2/2
Revenue grew 12.4% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 1/2
Moderate debt to equity (62.1%), up to 100%.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 0/1
EBIT is 1.2x against interest expense, below 5x.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (2.1x) is below the industry median (4.0x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Compumedics Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Compumedics Ltd
Compumedics Limited engages in the research, development, manufacture, and distribution of medical equipment and associated technologies in the Americas, Australia, the Asia Pacific, Europe, and the Middle East. The company provides sleep diagnostics products, including Somfit/Somfit Pro, a wearable device for collecting patients' physiological data; Somté PSG; Grael PSG; Grael 4K PSG; Falcon HST; and Somté, an investigative tool. The company also offers neurology diagnostic…
Full company profileCompumedics Ltd financial statements
Compumedics Ltd annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 34.4M | 37.0M | 41.5M | 35.1M | 35.7M | 37.8M | 42.4M | 49.7M | 51.0M | 60.3M |
| Gross Profit | 19.1M | 21.2M | 24.8M | 18.0M | 19.2M | 19.3M | 21.6M | 26.1M | 31.0M | 31.0M |
| Operating Income | 1.42M | 2.58M | 4.54M | -756K | 398K | 137K | -3.53M | -812K | 714K | 1.79M |
| EBITDA | 2.70M | 4.18M | 5.78M | -5.42M | 2.56M | 3.31M | -5.05M | 2.79M | 2.96M | 3.99M |
| Net Income | 1.31M | 2.78M | 4.02M | -5.84M | 998K | 1.36M | -6.12M | -338K | -1.27M | 214K |
| EPS | 0.01 | 0.02 | 0.02 | -0.03 | 0.01 | 0.01 | -0.03 | 0.00 | -0.01 | 0.00 |
| Balance Sheet | ||||||||||
| Total Assets | 29.2M | 34.7M | 38.7M | 35.5M | 38.5M | 41.7M | 41.2M | 40.4M | 54.4M | 56.6M |
| Total Liabilities | 9.18M | 11.5M | 11.3M | 13.7M | 16.4M | 18.1M | 22.9M | 22.1M | 32.6M | 33.9M |
| Shareholders' Equity | 20.1M | 23.2M | 27.3M | 21.8M | 22.2M | 23.6M | 18.3M | 18.2M | 21.8M | 22.7M |
| Cash & Short-term Investments | 4.10M | 3.91M | 4.60M | 6.41M | 6.77M | 7.29M | 3.80M | 1.89M | 2.69M | 6.15M |
| Total Debt | 715K | 1.89M | 1.59M | 4.80M | 5.82M | 6.55M | 9.47M | 8.58M | 13.9M | 14.1M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 864K | 559K | 5.14M | 5.38M | 1.32M | 3.29M | 49.0K | 2.00M | 681K | 6.61M |
| Capital Expenditure | 148K | 208K | 1.31M | 4.23M | 1.55M | 2.99M | 4.41M | 2.99M | 214K | 181K |
| Free Cash Flow | 716K | 351K | 3.82M | 1.15M | -230K | 302K | -4.36M | -986K | 467K | 6.42M |
| Ratios | ||||||||||
| ROE | 6.5% | 12.0% | 14.7% | -26.8% | 4.5% | 5.8% | -33.5% | -1.9% | -5.8% | 0.9% |
| ROA | 4.5% | 8.0% | 10.4% | -16.4% | 2.6% | 3.3% | -14.9% | -0.8% | -2.3% | 0.4% |
| Net Profit Margin | 3.8% | 7.5% | 9.7% | -16.6% | 2.8% | 3.6% | -14.4% | -0.7% | -2.5% | 0.4% |
| Debt to Equity | 0.04x | 0.08x | 0.06x | 0.22x | 0.26x | 0.28x | 0.52x | 0.47x | 0.64x | 0.62x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Compumedics Ltd dividends
Compumedics Ltd has not paid dividends in the last 10 fiscal years.
Who owns Compumedics Ltd
- Insiders 63.96%
- Institutions 3.75%
- Public & others 32.29%
- Shares outstanding 200M
- Free float 76.6M
Compumedics Ltd company profile
- Company name
- Compumedics Ltd
- Ticker
- CMP.AU
- ISIN
- AU000000CMP2
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 175
- Fiscal year end
- June
- Address
- 30-40 Flockhart Street, Abbotsford, VIC, Australia, 3067
- Phone
- 61 3 8420 7300
- Website
- compumedics.com.au
About Compumedics Ltd
Compumedics Limited engages in the research, development, manufacture, and distribution of medical equipment and associated technologies in the Americas, Australia, the Asia Pacific, Europe, and the Middle East. The company provides sleep diagnostics products, including Somfit/Somfit Pro, a wearable device for collecting patients' physiological data; Somté PSG; Grael PSG; Grael 4K PSG; Falcon HST; and Somté, an investigative tool. The company also offers neurology diagnostics, such as ONsight A.V.S. for monitoring patient's home ambulatory studies; Grael 4K PSG:EEG, Grael 4K-EEG, and Grael LT EEG System amplifiers; Neuvo 64-512 Channel LTM EEG monitoring systems; Okti, a portable EEG amplifier; and Siesta 802, a multi-functional ambulatory recording device. In addition, it provides software products, such as Profusion Sleep software suite; Profusion EEG Software; Profusion neXus 360, a web-based patient data and lab management system that offers integrated hardware and software solutions for sleep and neurology clinics; CURRY, a signal processing and source localization multi-modal neuroimaging suite; Profusion neXus Scheduler for planning for staff and time; Somte and Persyst Software; HD Digital Video; Profusion Plus; ECG Free software; and TCM5 FLEX Transcutaneous Monitor, Grael DC, Siesta extended battery pack, and Summit IP products. Further, the company offers brain research technologies; pharmaceutical clinical trials and research services; and consumables and supplies for diagnostic and research solutions. The company was incorporated in 1987 and is headquartered in Abbotsford, Australia.
Compumedics Ltd management
5- Dr. David Burton Ph.D.Founder, Executive Chairman & CEO · born 1959
- Mr. David Francis LawsonCFO, Company Secretary & Executive Director · born 1965
- Mr. Warwick FreemanChief Technology Officer
- Dr. Kerry Trent HubickLegal Counsel and Trademark, Patent & General Legal Attorney
- Mr. Michael StoneChief Commercial Officer - US operations